Payment overview · 2025
General Payments
$91.92
5 reported records · 4 companies
Healthcare provider profile · identity verified
Suzanne Scott, MD
Allopathic & Osteopathic Physicians|Family Medicine · BROCKWAY, PA · NPI 1972520401
Verified facts
What the public records show
CMS Open Payments records show Suzanne Scott, MD received $91.92 in general payments during 2025 across 5 reported records.
AstraZeneca Pharmaceuticals LP accounted for 35.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Farxiga by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 376 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Nurtec Odt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $32.91 | 35.8% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $20.89 | 22.7% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $19.95 | 21.7% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $18.17 | 19.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $91.92 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $32.91 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $20.89 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $19.95 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $18.17 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $18.17 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $18.17 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
376 | 37 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 587 | 104 |
| Atorvastatin Calcium | Atorvastatin Calcium | 551 | 124 |
| Amlodipine Besylate | Amlodipine Besylate | 453 | 109 |
| Eliquis | Apixaban | 376 | 37 |
| Gabapentin | Gabapentin | 361 | 63 |
| Lisinopril | Lisinopril | 351 | 91 |
| Pantoprazole Sodium | Pantoprazole Sodium | 341 | 67 |
| Sertraline Hcl | Sertraline Hcl | 283 | 47 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 278 | 39 |
| Potassium Chloride | Potassium Chloride | 257 | 41 |
| Metoprolol Succinate | Metoprolol Succinate | 248 | 45 |
| Trazodone Hcl | Trazodone Hcl | 241 | 45 |
| Lorazepam | Lorazepam | 218 | 38 |
| Furosemide | Furosemide | 207 | 41 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 202 | 53 |
| Omeprazole | Omeprazole | 190 | 46 |
| Simvastatin | Simvastatin | 179 | 39 |
| Metoprolol Tartrate | Metoprolol Tartrate | 177 | 35 |
| Losartan Potassium | Losartan Potassium | 173 | 36 |
| Prednisone | Prednisone | 154 | 76 |
| Carvedilol | Carvedilol | 148 | 28 |
| Famotidine | Famotidine | 140 | 23 |
| Hydrochlorothiazide | Hydrochlorothiazide | 138 | 39 |
| Fluticasone Propionate | Fluticasone Propionate | 136 | 60 |
| Xarelto | Rivaroxaban | 135 | 13 |
| Bumetanide | Bumetanide | 133 | 24 |
| Montelukast Sodium | Montelukast Sodium | 130 | 25 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 127 | 41 |
| Escitalopram Oxalate | Escitalopram Oxalate | 120 | 23 |
| Tamsulosin Hcl | Tamsulosin Hcl | 115 | 20 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 113 | 22 |
| Fluoxetine Hcl | Fluoxetine Hcl | 105 | 19 |
| Metformin Hcl | Metformin Hcl | 105 | 27 |
| Tramadol Hcl | Tramadol Hcl | 103 | 24 |
| Allopurinol | Allopurinol | 98 | 19 |
| Tizanidine Hcl | Tizanidine Hcl | 97 | 18 |
| Clonazepam | Clonazepam | 91 | 17 |
| Metformin Hcl Er | Metformin Hcl | 91 | 25 |
| Meloxicam | Meloxicam | 85 | 26 |
| Ozempic | Semaglutide | 81 | 12 |
| Clopidogrel | Clopidogrel Bisulfate | 78 | 17 |
| Mirtazapine | Mirtazapine | 78 | 12 |
| Oxycodone Hcl | Oxycodone Hcl | 78 | 21 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 75 | 65 |
| Jardiance | Empagliflozin | 74 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 72 | 12 |
| Levetiracetam | Levetiracetam | 70 | suppressed |
| Valsartan | Valsartan | 69 | 19 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 68 | 20 |
| Warfarin Sodium | Warfarin Sodium | 68 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 67 | 15 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 66 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 63 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 61 | 19 |
| Donepezil Hcl | Donepezil Hcl | 61 | suppressed |
| Sucralfate | Sucralfate | 61 | suppressed |
| Atenolol | Atenolol | 59 | suppressed |
| Bupropion Xl | Bupropion Hcl | 58 | suppressed |
| Mounjaro | Tirzepatide | 57 | suppressed |
| Spironolactone | Spironolactone | 57 | 12 |
| Amoxicillin | Amoxicillin | 56 | 30 |
| Buspirone Hcl | Buspirone Hcl | 56 | suppressed |
| Synthroid | Levothyroxine Sodium | 56 | 12 |
| Memantine Hcl | Memantine Hcl | 55 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 55 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 55 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 54 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 53 | suppressed |
| Pregabalin | Pregabalin | 53 | 13 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 53 | 28 |
| Alprazolam | Alprazolam | 50 | 13 |
| Finasteride | Finasteride | 50 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 49 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 48 | suppressed |
| Ezetimibe | Ezetimibe | 47 | suppressed |
| Glipizide Er | Glipizide | 47 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 46 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 46 | suppressed |
| Torsemide | Torsemide | 46 | suppressed |
| Tradjenta | Linagliptin | 45 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 44 | 20 |
| Celecoxib | Celecoxib | 43 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 43 | 33 |
| Kapspargo Sprinkle | Metoprolol Succinate | 43 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 42 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 42 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 42 | 17 |
| Pioglitazone Hcl | Pioglitazone Hcl | 41 | suppressed |
| Azithromycin | Azithromycin | 40 | 34 |
| Myrbetriq | Mirabegron | 40 | suppressed |
| Topiramate | Topiramate | 40 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 37 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 36 | suppressed |
| Cephalexin | Cephalexin | 34 | 26 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 34 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 33 | suppressed |
| Entresto | Sacubitril/Valsartan | 33 | suppressed |
| Ondansetron Odt | Ondansetron | 33 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 33 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 33 | 17 |
| Zolpidem Tartrate | Zolpidem Tartrate | 33 | suppressed |
| Glimepiride | Glimepiride | 32 | suppressed |
| Hydrocortisone | Hydrocortisone | 32 | 11 |
| Ramipril | Ramipril | 32 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 31 | 21 |
| Breo Ellipta | Fluticasone/Vilanterol | 31 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 31 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 30 | suppressed |
| Lamotrigine | Lamotrigine | 30 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 30 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 30 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 30 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 29 | 12 |
| Methylprednisolone | Methylprednisolone | 29 | 26 |
| Telmisartan | Telmisartan | 29 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 28 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 28 | suppressed |
| Irbesartan | Irbesartan | 28 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Nystatin | Nystatin | 27 | 15 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 27 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 27 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 26 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 26 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 26 | suppressed |
| Safetyglide Insulin Syringe | Syringe,needle,insuln,sf 0.5ml | 26 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 25 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 25 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 25 | 11 |
| Enalapril Maleate | Enalapril Maleate | 24 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 24 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 24 | suppressed |
| Risperidone | Risperidone | 23 | suppressed |
| Temazepam | Temazepam | 22 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 21 | suppressed |
| Fenofibrate | Fenofibrate | 21 | suppressed |
| Loperamide | Loperamide Hcl | 21 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 21 | 16 |
| Lovastatin | Lovastatin | 20 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 20 | suppressed |
| Fluconazole | Fluconazole | 19 | 17 |
| Ibuprofen | Ibuprofen | 19 | suppressed |
| Olanzapine | Olanzapine | 19 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 19 | suppressed |
| Trulicity | Dulaglutide | 19 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 18 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 18 | suppressed |
| Phenytoin | Phenytoin | 18 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 18 | suppressed |
| Rybelsus | Semaglutide | 18 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 17 | suppressed |
| Lagevrio (Eua) | Molnupiravir | 17 | 16 |
| Valproic Acid | Valproic Acid | 17 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 16 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 16 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 16 | suppressed |
| Methocarbamol | Methocarbamol | 16 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Budesonide | Budesonide | 15 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 15 | suppressed |
| Fentanyl | Fentanyl | 15 | suppressed |
| Ketoconazole | Ketoconazole | 15 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 15 | suppressed |
| Xtampza Er | Oxycodone Myristate | 15 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Dutasteride | Dutasteride | 14 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 14 | suppressed |
| Klor-Con M20 | Potassium Chloride | 14 | suppressed |
| Prolia | Denosumab | 14 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 13 | suppressed |
| Calcitriol | Calcitriol | 13 | suppressed |
| Enbrel Sureclick | Etanercept | 13 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 13 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 13 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 13 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 13 | suppressed |
| Clobazam | Clobazam | 12 | suppressed |
| Folic Acid | Folic Acid | 12 | suppressed |
| Glipizide | Glipizide | 12 | suppressed |
| Nadolol | Nadolol | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Jantoven | Warfarin Sodium | 11 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 11 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 11 | suppressed |
| Prilosec | Omeprazole Magnesium | 11 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $91.92 · 5 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSUPRA, COMIRNATY, PREVNAR 20, REXULTI, Veozah | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error